Integrated Development Associates

Integrated Development Associates (IDA) is a Tokyo-based contract research organization (CRO) founded in 2004, specializing in assisting biopharmaceutical companies with drug development and commercialization strategies, particularly for integrating Japan and Asia into global development plans. Acquired by Chiltern in 2017, IDA operates as a subsidiary offering comprehensive services including regulatory pathway establishment (PMDA consultations, Sakigake designation support), clinical trial implementation across Asia, market positioning, patient identification, orphan drug applications, and J-NDA submissions. It holds a prestigious Sakigake (Forerunner Initiative) designation, accelerating regulatory approvals in Japan for its clients.